Efficacy of use of Enerion (sulbuthiamine) in asthenia treatment in patients having chronic non-infectious diseases in outpatient practice

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Asthenia is a common and at the same time alarming symptom of many chronic non-communicable diseases (CNCDs).

The aim: to estimate the efficacy of drug treatment of asthenia with Enerion (sulbutiamine) medicine in CNCDs patients in outpatient conditions.

Material and methods. An open prospective clinical study was performed. Screening for asthenia was made in 2373 outpatients with chronic NCDs, of which 847 persons (326 male and 521 female patients, mean age 60.6 ± 14.1 years) met the diagnostic criteria. A survey, collection of complaints and anamnesis, physical examination, and analysis of outpatient records of patients were carried out, on the basis of which CNCDs diagnosis was made. Using MFI-20 asthenia rating scale and FSS asthenia severity scale, subjective diagnosis of asthenia syndrome was established. All the participants were divided into 3 groups: 1st – 446 patients who did not receive anti-asthenic therapy and did not change their lifestyle; 2nd – 71 patients who changed only their lifestyle; 3rd – 330 patients who received Enerion 600 mg/day. within 4 weeks.

Results. In patients of the 3rd group, at the 1st screening of asthenia, a greater degree of severity was fixed on both scales in comparison with patients of the 1st and 2nd groups. Despite this, while taking sulbutiamine in group 3, there was a decrease and complete normalization of the total score by MFI-20 and FSS questionnaires. At the same time, the severity of asthenia in groups 1 and 2 also decreased, but did not reach norm level by MFI-20 assessment. Also, in the group of patients receiving sulbutiamine therapy, normalization of asthenia severity indexes was fixed for all its subtypes, and the total score for each of the MFI-20 subscales after a month of observation was significantly lower in comparison with both groups 1 and 2. There were no side effects associated with sulbutiamine during the study.

Conclusion. Our study is the first to demonstrate the positive effect of sulbutiamine (Enerion) on the symptoms of asthenia in a fairly large group of patients with CNCDs in outpatient practice. Active, targeted diagnosis of asthenic syndrome in patients with chronic NCDs by therapists will lead to the need to resolve the point concerning appropriateness of its pharmacotherapy, including the possibility of using sulbutiamine as a highly effective and safe medicine.

Full Text

Restricted Access

About the authors

Natalya Yu. Shimokhina

Professor V.F. Voino-Yasenetsky Krasnoyarsk State Medical University of the Ministry of Healthcare of Russia

Author for correspondence.
Email: doctorkardiolog99@rambler.ru
ORCID iD: 0000-0002-0091-5265
SPIN-code: 4910-4136

MD, Dr. Sci. (Medicine), associate professor of the Department of polyclinic therapy and family medicine with a course of postgraduate education

Russian Federation, Krasnoyarsk

Marina M. Petrova

Professor V.F. Voino-Yasenetsky Krasnoyarsk State Medical University of the Ministry of Healthcare of Russia

Email: stk99@yandex.ru
ORCID iD: 0000-0002-8493-0058
SPIN-code: 3531-2179

MD, Dr. Sci. (Medicine), professor, head of the Department of polyclinic therapy and family medicine with a course of postgraduate education

Russian Federation, Krasnoyarsk

Maria S. Bychkovskaya

Professor V.F. Voino-Yasenetsky Krasnoyarsk State Medical University of the Ministry of Healthcare of Russia

Email: marbyse@mail.ru
ORCID iD: 0009-0004-4084-5419

6th year student of the Faculty of general medicine

Russian Federation, Krasnoyarsk

References

  1. Avogo W.A. Community characteristics and the risk of non-communicable diseases in Ghana. PLOS Glob Public Health. 2023; 3(1): e0000692. https://doi.org/10.1371/journal.pgph.0000692. PMID: 36962739. PMCID: PMC10021620.
  2. Lima M.D.C., do Nascimento H.M.A., da Silva J.Y.P. et al. Evidence for the beneficial effects of Brazilian native fruits and their by-products on human intestinal microbiota and repercussions on non-communicable chronic diseases – a review. Foods. 2023; 12(18): 3491. https://doi.org/10.3390/foods12183491. PMID: 37761200. PMCID: PMC10527964.
  3. World Health Organization. Noncommunicable Diseases Progress Monitor 2022. URL: https://iris.who.int/bitstream/handle/10665/353048/9789240047761-eng.pdf?sequence=1 (date of access – 01.03.2024). ISBN (electronic version): 978-92-4-004776-1.
  4. Драпкина О.М., Концевая А.В., Калинина А.М. с соавт. Профилактика хронических неинфекционных заболеваний в Российской Федерации. Национальное руководство 2022. Кардиоваскулярная терапия и профилактика. 2022; 21(4): 5–232. [Drapkina O.M., Kontsevaya A.V., Kalinina A.M. et al. 2022 Prevention of chronic non-communicable diseases in the Russian Federation. National guidelines. Kardiovaskulyarnaya terapiya i profilaktika = Cardiovascular Therapy and Prevention. 2022; 21(4): 5–232 (In Russ.)]. https://doi.org/10.15829/1728-8800-2022-3235. EDN: DNBVAT.
  5. Maisel P., Baum E., Donner-Banzhoff N. Fatigue as the chief complaint–epidemiology, causes, diagnosis, and treatment. Dtsch Arztebl Int. 2021; 118(33–34): 566–76. https://doi.org/10.3238/arztebl.m2021.0192. PMID: 34196270. PMCID: PMC8579431.
  6. Goertz Y.M.J., Braamse A.M.J., Spruit M.A. et al. Fatigue in patients with chronic disease: Results from the population-based lifelines cohort study. Sci Rep. 2021; 11(1): 20977. https://doi.org/10.1038/s41598-021-00337-z. PMID: 34697347. PMCID: PMC8546086.
  7. Vaes A.W., Goertz Y.M.J., van Herck M. et al. Physical and mental fatigue in people with non-communicable chronic diseases. Ann Med. 2022; 54(1): 2522–34. https://doi.org/10.1080/07853890.2022.2122553. PMID: 36111684. PMCID: PMC9487929.
  8. Polikandrioti M., Kalafatakis F., Koutelekos I., Kokoularis D. Fatigue in heart failure outpatients: Levels, associated factors, and the impact on quality of life. Arch Med Sci Atheroscler Dis. 2019; 4: e103–e112. https://doi.org/10.5114/amsad.2019.85406. PMID: 31211277. PMCID: PMC6555087.
  9. Песковец Р.Д., Штарик С.Ю., Евсюков А.А. Распространенность тревожных расстройств в общемедицинской сети и их связь с сердечно-сосудистыми заболеваниями. Сибирское медицинское обозрение. 2019; 6(120): 73–79. [Peskovets R.D., Shtarik S.Yu., Evsyukov A.A. Prevalence of anxiety disorders in general medical network and their relationship with risk factors of cardiovascular diseases. Sibirskoye meditsinskoye obozreniye = Siberian Medical Review. 2019; 6(120): 73–79 (In Russ.)]. https://doi.org/10.20333/2500136-2019-6-73-79. EDN: ZRKCZP.
  10. Jaime-Lara R.B., Koons B.C., Matura L.A. et al. A qualitative metasynthesis of the experience of fatigue across five chronic conditions. J Pain Symptom Manage. 2020; 59(6): 1320–43. https://doi.org/10.1016/j.jpainsymman.2019.12.358. PMID: 31866485. PMCID: PMC7239763.
  11. Abbott Z., Summers W., Niehaus W. Fatigue in post-acute sequelae of coronavirus disease 2019. Phys Med Rehabil Clin N Am. 2023; 34(3): 607–21. https://doi.org/10.1016/j.pmr.2023.04.006. PMID: 37419535. PMCID: PMC10123359.
  12. Васенина Е.Е., Ганькина О.А. Хронический стресс и астения. Лечебное дело. 2023; (1): 29–38. [Vasenina E.E., Gankina O.A. Chronic stress and fatigue. Lechebnoe delo = General Medicine. 2023; (1): 29–38 (In Russ.)]. https://doi.org/10.24412/2071-5315-2023-12950. EDN: TPQPNG.
  13. Hulme K., Safari R., Thomas S. et al. Fatigue interventions in long term, physical health conditions: A scoping review of systematic reviews. PLoS One. 2018; 13(10): e0203367. https://doi.org/10.1371/journal.pone.0203367. PMID: 30312325. PMCID: PMC6193578.
  14. Machado M.O., Kang N.C., Tai F. et al. Measuring fatigue: A meta-review. Int J Dermatol. 2021; 60(9): 1053–69. https://doi.org/10.1111/ijd.15341. PMID: 33301180.
  15. Gecaite-Stonciene J., Bunevicius A., Burkauskas J. et al. Validation of the multidimensional fatigue inventory with coronary artery disease patients. Int J Environ Res Public Health. 2020; 17(21): 8003. https://doi.org/1010.3390/ijerph17218003. PMID: 33143183. PMCID: PMC7662819.
  16. Al Maqbali M., Hughes C., Gracey J. et al. Quality assessment criteria: psychometric properties of measurement tools for cancer related fatigue. Acta Oncol. 2019; 58(9): 1286–97. https://doi.org/10.1080/0284186X.2019.1622773. PMID: 31204538.
  17. Wondie Y., Hinz A. Application of the multidimensional fatigue inventory to Ethiopian cancer patients. Front Psychol. 2021; 12: 687994. https://doi.org/10.3389/fpsyg.2021.687994. PMID: 34925119. PMCID: PMC8674181.
  18. Binz C., Osmanovic A., Thomas N.H. et al. Validity and reliability of the German multidimensional fatigue inventory in spinal muscular atrophy. Ann Clin Transl Neurol. 2022; 9(3): 351–62. https://doi.org/10.1002/acn3.51520. PMID: 35191616. PMCID: PMC8935281.
  19. Jerkovic A., Prorokovic A., Matijaca M. et al. Validation of the fatigue severity scale in Croatian population of patients with multiple sclerosis disease: Factor structure, internal consistency, and correlates. Mult Scler Relat Disord. 2022; 58: 103397. https://doi.org/10.1016/j.msard.2021.103397. PMID: 35216780.
  20. Starling-Soares B., Carrera-Bastos P., Bettendorff L. Role of the synthetic B1 vitamin sulbutiamine on health. J Nutr Metab. 2020; 2020: 9349063. https://doi.org/10.1155/2020/9349063. PMID: 32399290. PMCID: PMC7210561.
  21. Enriquez-Flores S., De la Mora-De la Mora I., García-Torres I. et al. Human triosephosphate isomerase is a potential target in cancer due to commonly occurring post-translational modifications. Molecules. 2023; 28(16): 6163. https://doi.org/10.3390/molecules28166163. PMID: 37630415. PMCID: PMC10459230.
  22. Jonus H.C., Byrnes C.C., Kim J. et al. Thiamine mimetics sulbutiamine and benfotiamine as a nutraceutical approach to anticancer therapy. Biomed Pharmacother. 2020; 121: 109648. https://doi.org/10.1016/j.biopha.2019.109648. PMID: 31810115.
  23. Медведев В.Э. Пациент с астенией в общей медицинской практике. Терапия. 2022; 8(9): 107–113. [Medvedev V.E. Patient with asthenia in general medical practice. Terapiya = Therapy. 2022; 8(9): 107–113 (In Russ.)]. https://doi.org/10.18565/therapy.2022.9.107-113. EDN: GACOAM.
  24. Беккер Р.А., Быков Ю.В. Сульбутиамин в психиатрии, наркологии, неврологии и общесоматической медицине (обзор литературы). Siberian Journal of Life Sciences and Agriculture. 2020; 12(2): 41–72. [Bekker R.A., Bykov Yu.V. Sulbuthiamine in psychiatry, addiction medicine, neurology and general medicine (scientific review). Siberian Journal of Life Sciences and Agriculture. 2020; 12(2): 41–72 (In Russ.)]. https://doi.org/10.12731/2658-6649-2020-12-2-41-72. EDN: CJKJND.
  25. Быков Ю.В., Беккер Р.А. Специфическое лечение астенических состояний: в фокусе сульбутиамин. Терапевтический архив. 2022; 94(5): 689–694. [Bykov Yu.V., Bekker R.A. On the specific treatment of asthenic states: Focus on sulbutiamine. Terapevticheskiy arkhiv = Therapeutic Archive. 2022; 94(5): 689–694 (In Russ.)]. https://doi.org/10.26442/00403660.2022.05.201533. EDN: BCSTXN.
  26. Sevim S., Kaleagası H., Taşdelen B. Sulbutiamine shows promising results in reducing fatigue in patients with multiple sclerosis. Mult Scler Relat Disord. 2017; 16: 40–43. https://doi.org/10.1016/j.msard.2017.05.010. PMID: 28755683.
  27. Shah S.N.; Sulbutiamine Study Group. Adjuvant role of vitamin B analogue (sulbutiamine) with anti-infective treatment in infection associated asthenia. J Assoc Physicians India. 2003; 51: 891. PMID: 14710977.
  28. Kiew K.K., Mohamad W.W., Ridzuan A. et al. Effects of sulbutiamine on diabetic polyneuropathy: An open randomised controlled study in type 2 diabetics. Malays J Med Sci. 2002; 9(1): 21–27. PMID: 22969314. PMCID: PMC3436103.
  29. Гурак С.В., Парфенов В.А. Астения после инсульта и инфаркта миокарда и ее лечение Энерионом. Клиническая геронтология. 2005; 11(8): 9–12. [Gurak S.V., Parfenov V.A. Asthenia after stroke and myocardial infarction and its treatment with Enerion. Klinicheskaya gerontologiya = Clinical Gerontology. 2005; 11(8): 9–12 (In Russ.)]. EDN: HQUTCZ.
  30. Хасанова Д., Мухутдинова Э., Житкова Ю. Энерион (сульбутиамин) в лечении постинсультного астенического синдрома. Врач. 2008; (7): 66–69. [Khasanova D., Mukhutdinova E., Zhitkova Yu. Enerion (sulbutiamine) in the treatment of post-stroke asthenic syndrome. Vrach = The Doctor. 2008; (7): 66–69 (In Russ.)]. EDN: KXLKAP.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download
2. Fig. 1. Structure of chronic non-infectious diseases in patients with asthenia included in the study (number of patients, %)

Download (313KB)
Indexing metadata
3. Fig. 2. Dynamics of asthenia severity in patients with chronic non-infectious diseases included in the study

Download (379KB)
Indexing metadata

Copyright (c) 2024 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies